A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

To join this study, you would generally need to be a woman aged 18 or older with cervical cancer that has been confirmed by a doctor. This cancer must be either still present after treatment, have come back, or be newly diagnosed as metastatic (meaning it has spread) to other parts of your body. Importantly, your cancer should not be treatable with surgery or radiation.

There are also some health checks. For example, if you have HIV, hepatitis B, or hepatitis C, these conditions would need to be well controlled with treatment. Your general health and how well you can do daily activities (known as your performance status) also play a part. Doctors will also check specific features of your cancer cells to see if they match the study criteria.

However, some things would prevent you from joining. This includes certain types of severe eye problems, active inflammatory bowel disease, or serious heart or brain conditions that are not well controlled. You also couldn't join if you’ve recently had other cancer treatments (apart from what’s allowed in the study) or if you have certain other serious medical conditions or certain types of additional cancers that are actively growing or needing treatment.

If you decide to take part, the study involves two main parts. In the first part, a small group will receive sac-TMT, pembrolizumab, and bevacizumab. In the second part, everyone starts with standard initial cancer treatment. If your cancer doesn't get worse after this, you'll then be randomly assigned to get either pembrolizumab alone or sac-TMT plus pembrolizumab as a maintenance treatment. Depending on your doctor's decision, you might also receive bevacizumab.

Taking part means you'll have regular hospital visits for treatments, check-ups (including blood tests and scans) to monitor your health and how the treatment is working. The exact number of visits and the total length of your participation would be explained in detail by the study team, as it depends on whether you're in the first or second part of the study and how your body responds to the treatment. There will also be a follow-up period after your treatment finishes to monitor your long-term health.